JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Sana Biotechnology Inc

Închisă

SectorSănătate

5.55 -0.36

Rezumat

Modificarea prețului

24h

Curent

Minim

5.5

Maxim

5.61

Indicatori cheie

By Trading Economics

Venit

-44M

-94M

Marjă de profit

-321.09

Angajați

194

EBITDA

-48M

-95M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+47.58% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

689M

1.4B

Deschiderea anterioară

5.91

Închiderea anterioară

5.55

Sentimentul știrilor

By Acuity

50%

50%

148 / 373 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

Sana Biotechnology Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 oct. 2025, 23:52 UTC

Market Talk

Global Equities Roundup: Market Talk

26 oct. 2025, 23:52 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

26 oct. 2025, 23:46 UTC

Market Talk

Oil Rises Amid Ongoing Supply Concerns -- Market Talk

26 oct. 2025, 23:41 UTC

Market Talk

Gold Falls; U.S.-China Trade Deal Optimism Overcomes Signs of Cooler U.S. Inflation -- Market Talk

26 oct. 2025, 23:34 UTC

Câștiguri

Sinopharm Group 9-Mos Oper Pft CNY10.87B Vs. Pft CNY10.84B >1099.HK

26 oct. 2025, 23:32 UTC

Câștiguri

Sinopharm Group 9-Mos Net CNY5.31B Vs. Net CNY5.28B >1099.HK

26 oct. 2025, 23:30 UTC

Câștiguri

Sinopharm Group 9-Mos Rev CNY431.48B Vs. CNY442.42B >1099.HK

26 oct. 2025, 22:29 UTC

Câștiguri

WuXi AppTec 3Q Rev CNY12.06B ; up 15.3% on Year>603259.SH

26 oct. 2025, 22:29 UTC

Câștiguri

WuXi AppTec: Higher Contributions From Contract Research Development and Manufacturing Organization Unit Supported Results>603259.SH

26 oct. 2025, 22:29 UTC

Câștiguri

WuXi AppTec: Results Also Boosted From Divestment Gains >603259.SH

26 oct. 2025, 22:29 UTC

Câștiguri

WuXi AppTec 3Q Net CNY5.13B ; up 82.9% on Year>603259.SH

26 oct. 2025, 22:16 UTC

Câștiguri

Stock Futures Rise Ahead of Mag 7 Earnings, Fed Decision -- Barrons.com

26 oct. 2025, 21:33 UTC

Achiziții, Fuziuni, Preluări

Novartis Agrees to Acquire Avidity Biosciences for $12 Billion -- WSJ

26 oct. 2025, 19:29 UTC

Achiziții, Fuziuni, Preluări

Novartis Deal Values Avidity Biosciences At $12 Billion -- Barrons.com

26 oct. 2025, 06:39 UTC

Câștiguri

CITIC Securities 3Q Rev CNY22.78B Vs. CNY15.96B >6030.HK

26 oct. 2025, 06:39 UTC

Câștiguri

CITIC Securities: Higher Income From Brokerage, Investment Banking Supported Results>6030.HK

26 oct. 2025, 06:39 UTC

Câștiguri

CITIC Securities 3Q Net CNY9.44B Vs. Net CNY6.23B >6030.HK

24 oct. 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24 oct. 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 oct. 2025, 21:07 UTC

Câștiguri

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 oct. 2025, 20:58 UTC

Câștiguri

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 oct. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24 oct. 2025, 20:40 UTC

Câștiguri

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 oct. 2025, 20:24 UTC

Câștiguri

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct. 2025, 20:23 UTC

Câștiguri

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 oct. 2025, 20:13 UTC

Câștiguri

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 oct. 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 oct. 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 oct. 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 oct. 2025, 19:33 UTC

Câștiguri

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

Comparație

Modificare preț

Sana Biotechnology Inc Așteptări

Obiectiv de preț

By TipRanks

47.58% sus

Prognoză pe 12 luni

Medie 8.25 USD  47.58%

Maxim 12 USD

Minim 5 USD

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSana Biotechnology Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

5 ratings

5

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

1.68 / 1.87Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Weak Bearish Evidence

Termen lung

No Evidence

Sentiment

By Acuity

148 / 373 Clasament în Sănătate

Sentimentul știrilor

Neutral

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
help-icon Live chat